Loading…
Loading…
HNGE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HNGE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HNGE and 80,000+ other tickers.
See exactly how HNGE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HNGE and 80,000+ other tickers.
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of needs, including general musculoskeletal care, acute injuries, persistent chronic pain, and post-operative rehabilitation. Furthermore, the company provides essential administrative and operational assistance.
Hinge Health has delivered an impressive near-50% rally in just over six weeks. I initially highlighted HNGE's 85% gross margins and innovative migraine care program as key growth drivers. The growth story remains compelling, but after the rapid appreciation, I am downgrading HNGE from 'strong buy' to 'buy.'
� 2025 Benzinga.com. Benzinga does not provide investment advice.
Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.
Insight Holdings Group executed a sale of 426,000 shares at $90.21 per share following a derivative exercise, totaling $38.4 million. The firm continues to maintain significant exposure to the company through derivative securities held indirectly.
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended June 30, 2026, after the U.S. financial markets close on Tuesday, August 4, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations webs.